Bio-Rad Laboratories, Inc. Class A (BIO)

294.13
NYSE
Prev Close 294.13
Day Low/High 0.00 / 0.00
52 Wk Low/High 220.05 / 345.15
Exchange NYSE
Shares Outstanding 29.80B
Market Cap 8.77B
Div & Yield N.A. (N.A)
Bio-Rad Laboratories (BIO) Upgraded From Hold to Buy

Bio-Rad Laboratories (BIO) Upgraded From Hold to Buy

Bio-Rad Laboratories (BIO) has been upgraded by TheStreet Ratings from Hold to Buy with a ratings score of B.

3 Stocks Improving Performance Of The Electronics Industry

3 Stocks Improving Performance Of The Electronics Industry

TheStreet highlights 3 stocks pushing the health services industry higher today.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,300 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: AKRX, BIO, BIO.B, GSK, HCKT, MDRX, NLNK, QLTY, STLY, TPC, TTMI Downgrades: BWC, DRYS, HAWK, HSC, INFI, LGCY, MG, NATR, NTLS, ZEUS Initiations: EVGN, MEG Read on to get TheStreet Quant Ratings' detailed report:

Bio-Rad Laboratories Larger Than S&P 500 Component Denbury Resources

Bio-Rad Laboratories Larger Than S&P 500 Component Denbury Resources

In the latest look at stocks ordered by largest market capitalization, Russell 3000 component Bio-Rad Laboratories, Inc. was identified as having a larger market cap than the smaller end of the S&P 500, for example Denbury Resources, Inc.

Bio-Rad Laboratories (BIO) Downgraded From Buy to Hold

Bio-Rad Laboratories (BIO) Downgraded From Buy to Hold

Bio-Rad Laboratories (BIO) has been downgraded by TheStreet Ratings from Buy to Hold with a ratings score of C+.

Ratings Changes Today

Upgrades: FONR, TRR Downgrades: BIO, KOSS, XXIA Initiations: None Read on to get TheStreet Quant Ratings' detailed report:

Bio-Rad Laboratories Inc Stock Upgraded (BIO)

Bio-Rad Laboratories Inc Stock Upgraded (BIO)

Bio-Rad Laboratories (NYSE:BIO) has been upgraded by TheStreet Ratings from a hold to buy.

Ratings Changes Today

Upgrades: BID, BIO, CHH, FMS, HPTX, PTRY, QLIK, RDI Downgrades: ARCO, CVU, DTV, EDU, FHN, GTE, IRG, MTSL, PBA Initiations: ECOM Read on to get TheStreet Quant Ratings' detailed report:

BioAlliance Pharma: FDA Approval Of Beleodaq™ (belinostat)

BioAlliance Pharma: FDA Approval Of Beleodaq™ (belinostat)

Regulatory News: BioAlliance Pharma SA (Paris:BIO), an innovative Company specialized in the development of drugs in orphan oncology diseases, today announced that the U.

Bio-Rad Laboratories Inc Stock Downgraded (BIO)

Bio-Rad Laboratories Inc Stock Downgraded (BIO)

Bio-Rad Laboratories (NYSE:BIO) has been downgraded by TheStreet Ratings from from a buy to hold.

Ratings Changes Today

Upgrades: BORN, ESV, SIRI Downgrades: BIO, CIT, CNTF, EBMT, ICH, IDSY, IEP, NGVC, NICK, NWY Initiations: CCH, LVNTA, LVNTB Read on to get TheStreet Quant Ratings' detailed report:

Bio-Rad Laboratories Breaks Below 200-Day Moving Average - Notable for BIO

Bio-Rad Laboratories Breaks Below 200-Day Moving Average - Notable for BIO

In trading on Tuesday, shares of Bio-Rad Laboratories, Inc. crossed below their 200 day moving average of $122.38, changing hands as low as $122.07 per share.

Bio-Rad Laboratories Inc. Stock Upgraded (BIO)

Bio-Rad Laboratories Inc. Stock Upgraded (BIO)

Bio-Rad Laboratories (NYSE:BIO) has been upgraded by TheStreet Ratings from a hold to buy.

Ratings Changes Today

Upgrades: BIO, BMR, CAE, FNP, GRFS, HPT, RRC, RRD, Y Downgrades: CATO, CPHC, CRZO, RCKY, SPN, TRLA Initiations: LPDX Read on to get TheStreet Quant Ratings' detailed report:

Bio-Rad Laboratories Larger Than S&P 500 Component Cliffs Natural Resources

Bio-Rad Laboratories Larger Than S&P 500 Component Cliffs Natural Resources

In the latest look at stocks ordered by largest market capitalization, Russell 3000 component Bio-Rad Laboratories, Inc. was identified as having a larger market cap than the smaller end of the S&P 500, for example Cliffs Natural Resources, Inc.

4 Stocks Rising on Unusual Volume

4 Stocks Rising on Unusual Volume

Often when above-average volume moves into an equity, it precedes a large spike in volatility.

BioAlliance Pharma: Approval To Start ReLive (Livatag®) Phase III Clinical Trial In Primary Liver Cancer In The U.S. And Germany

BioAlliance Pharma: Approval To Start ReLive (Livatag®) Phase III Clinical Trial In Primary Liver Cancer In The U.S. And Germany

Regulatory News: BioAlliance Pharma SA (Euronext Paris - BIO), an innovative Company dedicated to the development of orphan oncology and to supportive care products, announces that it has received...

Bio-Rad Laboratories Larger Than S&P 500 Component Abercrombie & Fitch

Bio-Rad Laboratories Larger Than S&P 500 Component Abercrombie & Fitch

In the latest look at stocks ordered by largest market capitalization, Russell 3000 component Bio-Rad Laboratories, Inc. was identified as having a larger market cap than the smaller end of the S&P 500, for example Abercrombie & Fitch Co.

Bio-Rad Laboratories Inc. Stock Downgraded (BIO)

Bio-Rad Laboratories Inc. Stock Downgraded (BIO)

Bio-Rad Laboratories (NYSE:BIO) has been downgraded by TheStreet Ratings from from a buy to hold.

Ratings Changes Today

Upgrades: GIVN, WLDN, WVVI Downgrades: BIO, BRT, DF, GES, HMY, LYTS, SENEA, UUU, YDKN Initiations: AMRE, DFRG Read on to get TheStreet Quant Ratings' detailed report:

BIO Makes Notable Cross Below Critical Moving Average

BIO Makes Notable Cross Below Critical Moving Average

In trading on Tuesday, shares of Bio-Rad Laboratories, Inc. crossed below their 200 day moving average of $115.31, changing hands as low as $114.77 per share.

Bio-Rad Laboratories' CEO Discusses Q2 2012 Results - Earnings Call Transcript

Bio-Rad Laboratories' CEO Discusses Q2 2012 Results - Earnings Call Transcript

Bio-Rad Laboratories' CEO Discusses Q2 2012 Results - Earnings Call Transcript

BioAlliance Pharma SA: Initiation Of ReLive, Phase III Clinical Trial With Livatag® In Primary Liver Cancer

BioAlliance Pharma SA: Initiation Of ReLive, Phase III Clinical Trial With Livatag® In Primary Liver Cancer

Regulatory News: BioAlliance Pharma SA (Euronext Paris:BIO), a Company dedicated to orphan oncology products and specialty products, today announces the initiation of ReLive, its phase III clinical trial with...

Bio-Rad Laboratories' CEO Discusses Q1 2012 Results - Earnings Call Transcript

Bio-Rad Laboratories' CEO Discusses Q1 2012 Results - Earnings Call Transcript

Bio-Rad Laboratories' CEO Discusses Q1 2012 Results - Earnings Call Transcript

Bio-Rad Laboratories' CEO Discusses Q4 2011 Results - Earnings Call Transcript

Bio-Rad Laboratories' CEO Discusses Q4 2011 Results - Earnings Call Transcript

Bio-Rad Laboratories' CEO Discusses Q4 2011 Results - Earnings Call Transcript

Bio-Rad Laboratories' CEO Discusses Q3 2011 Results - Earnings Call Transcript

Bio-Rad Laboratories' CEO Discusses Q3 2011 Results - Earnings Call Transcript

Bio-Rad Laboratories' CEO Discusses Q3 2011 Results - Earnings Call Transcript

8 Health Care Stocks to Buy

8 Health Care Stocks to Buy

HCA Holdings, Thermo Fisher and Covidien are defensive bets to beat market volatility, according to analysts.

TheStreet Quant Rating: A- (Buy)